What are the diagnostic criteria for acute‑on‑chronic liver failure (ACLF) using the CLIF‑C (Chronic Liver Failure‑Consortium) definition?

ACLF Diagnostic Criteria

The EASL-CLIF (European Association for the Study of the Liver - Chronic Liver Failure Consortium) definition is the most widely accepted and validated diagnostic framework for ACLF, characterized by organ failure(s) in patients with cirrhosis presenting with acute decompensation and associated with ≥20% 28-day mortality. 1

Core CLIF-C Diagnostic Components

The EASL-CLIF criteria define ACLF based on organ failure assessment across six organ systems using the CLIF-SOFA (Sequential Organ Failure Assessment) score 1:

Six Organ Systems Evaluated:

• Liver failure: Bilirubin ≥12 mg/dL
• Kidney failure: Creatinine ≥2.0 mg/dL or renal replacement therapy
• Cerebral failure: Grade III-IV hepatic encephalopathy
• Coagulation failure: INR ≥2.5
• Circulatory failure: Use of vasopressors
• Respiratory failure: PaO2/FiO2 ≤200 or SpO2/FiO2 ≤200

ACLF Grading System:

ACLF Grade 1:

• Single kidney failure, OR
• Single non-renal organ failure + serum creatinine 1.5-1.9 mg/dL and/or Grade I-II hepatic encephalopathy
• 28-day mortality: ~23%

ACLF Grade 2:

• Two organ failures
• 28-day mortality: ~32-40%

ACLF Grade 3:

• Three or more organ failures
• 28-day mortality: ~74%

1, 2

Key Distinguishing Features from Other Definitions

The CLIF-C criteria differ substantially from competing definitions and demonstrate superior prognostic capability 3, 4:

EASL-CLIF vs. NACSELD:

The North American NACSELD definition requires ≥2 extrahepatic organ failures but misses 51.2% of EASL-CLIF Grade 3 patients and shows inferior mortality prediction (AUROC 0.561 vs. 0.710 for 28-day mortality) 3. NACSELD captures only the most severe, often preterminal patients and excludes liver dysfunction severity 5.

EASL-CLIF vs. APASL:

The Asian-Pacific APASL definition restricts ACLF to acute intrahepatic precipitants only, excludes bacterial infections and GI bleeding as triggers, and includes non-cirrhotic chronic liver disease—making it overly sensitive but non-specific (most patients survive beyond 28 days) 5, 1.

Clinical Context and Application

ACLF develops in approximately one-third of hospitalized patients with acute decompensation (ascites, encephalopathy, GI hemorrhage), either at admission or during hospitalization 1, 2. The syndrome is characterized by:

• Systemic inflammation driving multi-organ dysfunction
• Acute precipitants in ~60-70% of cases (infection, alcoholic hepatitis, viral reactivation, GI bleeding, surgery)
• Rapid clinical deterioration over days to weeks
• Potential reversibility with aggressive organ support and precipitant treatment

Pre-ACLF State:

The PREDICT study identified a "pre-ACLF" subgroup with decompensated cirrhosis at high risk for progression, characterized by elevated inflammatory markers (CRP, WBC) and higher CLIF-C AD, MELD, and MELD-Na scores, though no specific biomarker accurately predicts ACLF development 5.

Practical Diagnostic Algorithm

Step 1: Identify acute decompensation in a patient with known or suspected cirrhosis requiring hospitalization

Step 2: Assess all six organ systems using CLIF-SOFA criteria (specific cutoffs above)

Step 3: Count organ failures meeting threshold criteria

Step 4: Grade ACLF severity (0,1,2, or 3) based on number and pattern of organ failures

Step 5: Calculate CLIF-C ACLF score for mortality prediction (incorporates age, white blood cell count, and organ failures)

Important Clinical Caveats

The 2024 AASLD guidance proposes minimum diagnostic requirements that synthesize across definitions 5:

1. Acute onset with rapid clinical deterioration
2. Liver failure (elevated bilirubin AND elevated INR) in patients with chronic liver disease ± cirrhosis
3. At least one extrahepatic organ failure (neurologic, circulatory, respiratory, or renal)

This represents a practical compromise acknowledging that optimal laboratory cutoffs remain debated (INR 1.5-2.5, bilirubin 5-12 mg/dL across definitions) 5.

Critical pitfall: The EASL-CLIF definition includes some patients with decompensated cirrhosis whose condition may be irreversible, while NACSELD captures only preterminal patients—neither perfectly identifies the "sweet spot" of potentially reversible organ failure 5. The CLIF-C criteria demonstrate the best balance of sensitivity and prognostic accuracy in comparative studies 3, 4.

Modified EASL-CLIF criteria have been proposed for easier bedside use (renal failure as creatinine ≥2.35 mg/dL, coagulation failure as INR ≥2.0, with ACLF grade directly reflecting number of organ failures), showing slightly improved prognostic performance (AUROC 0.842 vs. 0.835) 6.